Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) is a Ahmedabad, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,12,020 Cr, it ranks #91 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,129.40 (as of 25 Oct 2026), the share price is 8.3% below its 52-week high of ₹1,232.10 and 35.2% above its 52-week low of ₹835.50. The share price is up 14.7% over one year and up 1.9% over three months.
| Current Price | ₹1,129.40 |
|---|---|
| Market Cap | ₹1,12,020 Cr |
| NSE Symbol | ZYDUSLIFE |
| BSE Code | 532321 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.2 |
| Return on Equity | 18.32% |
| Return on Assets | 8.13% |
| 52-Week Range | ₹835.50 – ₹1,232.10 |
| 1-Year Price Change | +14.7% |
| 3-Month Price Change | +1.9% |
| Beta (1Y) | 0.27 |
| Dividend Yield | 0.09% |
| Headquarters | Ahmedabad, Gujarat |
| Website | zyduslife.com |
| Revenue | ₹8,017 Cr |
|---|---|
| Net Profit | ₹952 Cr |
| Net Margin | 11.9% |
| EPS (Basic) | ₹9.35 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopa
1. Pharmaceuticals-This segment engages in the research, development, production, marketing, and distribution of active pharmaceutical ingredients and human formulations. 2. Consumer Products-This segment engages in the development, production, marketing, and distribution of health and wellness products. 3. Segment Adjustment-0
1. Pharmaceuticals (excl. Medical Technologies)-82.6% 2. Consumer Products-14.6% 3. Medical Technologies-2.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Zydus Lifesciences Ltd is trading at ₹1,129.40, with a market capitalisation of ₹1,12,020 Cr.
Zydus Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Zydus Lifesciences Ltd has a P/E of 22.2 and a return on equity of 18.32%.
Zydus Lifesciences Ltd is listed on the NSE under the symbol ZYDUSLIFE and on the BSE under the scrip code 532321.
Zydus Lifesciences Ltd's share price is up 14.7% over one year and up 1.9% over three months. Its 52-week range is ₹835.50 to ₹1,232.10.
In Q1 FY27, Zydus Lifesciences Ltd reported revenue of ₹8,017 Cr and net profit of ₹952 Cr, with basic EPS of ₹9.35 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.